1-5 of 5
Priyank P. Patel, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Craig A. Portell, MD, N. Nora Bennani, MD, Opeyemi Jegede, PhD, Seema Naik, MD, Benjamin M Parsons, DO, Priyank P Patel, MD, Christopher M. Reynolds, MD, Brad S. Kahl, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5243.
https://doi.org/10.1182/blood-2019-122759
Published: 2019
Journal Articles

Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)

Cory Mavis, BSc, MSc, Pallawi Torka, MD, Alison Zeccola, Priyank P. Patel, MD, Juan Gu, MD PhD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1542.
https://doi.org/10.1182/blood.V130.Suppl_1.1542.1542
Published: 2017
Journal Articles

Pre-Clinical Investigation of Targeted Therapies for Double Hit Diffuse Large B-Cell Lymphoma (DH-DLBCL)

Priyank P. Patel, MD, Alison Zeccola, Vishala T. Neppalli, MD, Juan J Gu, PhD, Cory Mavis, MSc, Sheila Sait, PhD, Francisco J. Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2015) 126 (23): 5122.
https://doi.org/10.1182/blood.V126.23.5122.5122
Published: 2015
Journal Articles

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Pallawi Torka, MD, Priyank P. Patel, MD, Wei Tan, Gregory Wilding, Seema A. Bhat, MD, Myron S. Czuczman, MD, Kelvin P. Lee, MD, George Deeb, MD, Vishala T. Neppalli, MD, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2015) 126 (23): 3975.
https://doi.org/10.1182/blood.V126.23.3975.3975
Published: 2015
Journal Articles

Intense Cytarabine-Based Chemo-Immunotherapy, Central Nervous System (CNS) Prophylaxis and Early High-Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS) in First Remission Are Associated with an Improved Clinical Outcome in Double-Hit (DHL)/Triple-Hit (THL) Diffuse Large B-Cell Lymphoma (DLBCL)

Priyank P. Patel, MD, Pallawi Torka, MD, Vishala T. Neppalli, MD, George Deeb, MD, Sheila N.J. Sait, PhD, AnneMarie W. Block, PhD, Seema A. Bhat, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2014) 124 (21): 3031.
https://doi.org/10.1182/blood.V124.21.3031.3031
Published: 2014